Whether you're validating a binding mechanism for publication or screening a million-compound library for a lead candidate, the same rigorous simulation stack underpins both engagements — only the deliverables change.
For structural biology, biochemistry, pharmacology, and chemical biology research groups that need heavy computational horsepower, trajectory calculations, and rigorous data analysis to validate experimental findings.
For early-stage biotech startups, pharmaceutical firms, and CDMOs looking to reduce physical screening costs, optimize hit compounds, and accelerate lead identification.
From target preparation to lead optimization, our integrated in-silico pipeline spans the complete arc of structure-based drug discovery.
Rotate a live target–ligand complex in 3D, or flip to a 2D interaction map showing key residue contacts, hydrogen bonds, and pi-stacking.
Structures are loaded live from the RCSB Protein Data Bank for illustration. Client deliverables use target coordinates and simulation trajectories specific to each project.
A staged filter that narrows a chemical library down to a shortlist worth synthesizing.
Industry-standard software packages for docking, simulation, free-energy analysis, and trajectory visualization.
Featured Software Suite for Drug Discovery
A ray-traced 3D protein-ligand complex paired with a 2D residue interaction schematic and RMSD/RMSF plots — ready for journal submission.
A ranked shortlist of lead candidates from the virtual screening funnel, with binding free-energy scores and predictive ADMET liability flags.